A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Irinotecan (Primary) ; Bevacizumab; Fluorouracil; Folinic acid
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms DOUBLIRI
- 30 Jan 2017 Status changed from recruiting to completed.
- 08 Jan 2016 New trial record